Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Carboplatin and Weekly Paclitaxel in Ovarian Cancer
NCT01097746Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2010
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01097746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097746.